Hikal starts construction of multiproduct API plant

Published: 28-Oct-2011
Manufacturing Ingredients

Will be operational by June 2012

Hikal starts construction of multiproduct API plant
Hikal, an Indian supplier of active ingredients and intermediates to the pharmaceutical industry, has started construction of a new multipurpose, multiproduct API plant, which will be operational by June 2012.

The flexible plant will be able to manufacture four APIs simultaneously under GMP and consists of two parallel streams running simultaneously with quick changeover capability.

The plant will also be able to accommodate 32 reactors with capacities ranging from 6m3 to 10m3, resulting in a total reactor volume of approximately 300m3.

A wide range of reactions will be carried out in the new plant, including nitration, liquid phase Oppenauer oxidation, Swern oxidation, Suzuki reaction, chiral synthesis, Mannich reaction, Friedel Craft reactions and more.

The firm says the reactors will be a combination of stainless steel and glass lined. Equipment for isolation and drying such as agitated nutsch filters, centrifuges and various types of dryers will also be installed.

Hikal has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Bangalore (Jigani), including an r&D centre and a dedicated contract research facility, Acoris Research, in Pune.

See more

You may also like

Ingredients
Hikal completes third US FDA audit in Bangalore

Hikal completes third US FDA audit in Bangalore

Read more
Indian ingredients manufacturer will ramp up new products under validation

Trending Articles

  1. FDA escalates action against Dabur India over systemic data-integrity and cGMP failures The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
  2. Roller compaction: stable, continuous production for oral solid dosage forms PCI’s David O’Connell examines how dry granulation supports sensitive formulations, improves powder handling and enables the controlled and scalable manufacture of granules for sachets, capsules and tablets
  3. Thermo Fisher Scientific launches new general purpose centrifuges with natural refrigerant cooling New X2 and S2 Series centrifuges combine precise performance with improved sustainability for research, biopharma and clinical laboratories
  4. Brenntag launches BYPHAR biopharma raw material portfolio spanning R&D through commercial GMP manufacture The three-tier range — covering non-GMP research materials through LBLE critical-grade excipients — consolidates regulatory documentation, global supply reliability and technical support for mAbs, CGT, ADCs and nucleic acid production under one brand
  5. DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Indian ingredients manufacturer will ramp up new products under validation
Media

Acoris and c-LEcta to develop synthetic routes for chiral compounds

<p>Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.</p>
Ingredients

Hikal signs API contract manufacturing agreement with Pfizer

<p>Indian outsourcing company Hikal has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (APIs) with Pfizer. Terms of the agreement were not disclosed.</p>
Manufacturing
Edwards cryogenic portfolio now available globally

Edwards cryogenic portfolio now available globally

Bringing cryogenic cooling and vacuum technologies together in one integrated portfolio for customers worldwide
Manufacturing
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs

SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs

Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Portable gas detection in the pharmaceutical sector

Portable gas detection in the pharmaceutical sector

Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
New legal duties for QPs in decentralised manufacturing

New legal duties for QPs in decentralised manufacturing

In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Subscribe now